logo-loader
viewOkyo Pharma Limited

OKYO Pharma Limited appoints top Beverly Hills surgeon to lead its Scientific Advisory Board

Dr James Khodabakhsh MD speaks to Proactive's Andrew Scott following his appointment as chair of OKYO Pharma Limited's (LON:OKYO) Scientific Advisory Board. He'll be tasked with bringing together a small group of leaders to review and inform the company's plans to progress its lead product candidate Chemerin to an IND in the indication of dry-eye disease.

Quick facts: Okyo Pharma Limited

Price: 10.125 GBX

LSE:OKYO
Market: LSE
Market Cap: £68.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Okyo Pharma Limited named herein, including the promotion by the Company of Okyo Pharma Limited in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

OKYO Pharma sees big opportunities for its dry eye and pain management...

Kunwar Shailubhai, chief scientific officer of OKYO Pharma Plc (LON:OKYO), discusses with Proactive's Andrew Scott the new direction and investment strategy for the business following its name change earlier this year. He says they've found two 'exciting' new technologies focused on dry...

on 12/9/18

2 min read